Video

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

In general, Hodgkin lymphoma is a very treatable disease, explains Schmitt. However, this may no longer apply to patients who are primarily refractory or have relapsed after standard treatment.

Schmitt investigated a preclinical study considering that a genetic or pharmacological approach to restore the B-cell phenotype of Hodgkin lymphoma cells could be therapeutic or could open the door for using treatment components such as antibodies or signaling inhibitors.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.